Introduction
============

The emergence of the novel coronavirus responsible for the severe acute respiratory syndrome (SARS) in 2002--2003 ([@bib9], [@bib19], [@bib20], [@bib25], [@bib31], [@bib32]) highlights the public health risks associated with the continual evolution of human coronaviruses. The coronaviruses are a diverse family of enveloped, positive-sense RNA viruses that are distributed widely among animal species ([@bib21]). The major surface glycoprotein, the spike (S) glycoprotein, mediates the attachment of virions to the host-cell receptor and the subsequent fusion of the viral and cellular membranes. The S glycoprotein is also the target of neutralizing antibodies and a major determinant of pathogenicity ([@bib21]).

The coronavirus S glycoproteins share similarities with other Class I viral fusion proteins in their apparent use of a six-membered α-helical coiled-coil structure to promote fusion of the viral and cellular membranes ([@bib3], [@bib7]). Class I viral fusion proteins, such as those of the retroviruses, filoviruses, orthomyxoviruses, and paramyxoviruses, contain two heptad-repeat regions, with a 3,4 periodicity in hydrophobic residues, that are poised to refold during virus entry to form a highly stable six-helix core ([@bib11], [@bib16], [@bib35], [@bib43], and references therein). In this structure, three α-helices formed by the C-terminal heptad repeats of the trimeric glycoprotein pack in an anti-parallel manner against conserved hydrophobic grooves on the surface of a central, three-stranded coiled coil formed by the N-terminal heptad repeats. Recent biophysical ([@bib3], [@bib17], [@bib23], [@bib40]) and, specifically, crystallographic ([@bib10], [@bib39], [@bib46]) studies of the SARS-CoV S glycoprotein fusion domain have demonstrated a six α-helical core structure typical of Class I viral fusion proteins. In contrast to other viruses, however, only a short central portion of the SARS-CoV C-terminal heptad-repeat region assumes the α-helical form in the crystal structure ([Fig. 1](#fig1){ref-type="fig"} ). The outlying heptad repeats appear as extended chains.Fig. 1SARS-CoV S glycoprotein and six-helix bundle. (A) Schematic drawing of S glycoprotein including S1 and S2 domains and the N- and C-terminal heptad-repeat regions. The C-terminal heptad-repeat region is expanded to show the amino acid sequence and the repeating hydrophobic ***a*** and ***d*** positions. Our analysis spans residues V1158 through L1182. Other landmarks include the signal peptide (sp), the receptor-binding domain (RBD) in S1, and the transmembrane (TM) and cytoplasmic (cyto) domains in S2. Sequence homology was used to approximate the location of the S1--S2 boundary, as the furin protease recognition site that is cleaved in Group 2 coronaviruses to form discrete S1 and S2 subunits is absent in the SARS-CoV S glycoprotein (see [Discussion](#sec1){ref-type="sec"}). (B) Rendering of the six-helix bundle structure from reference ([@bib46]) (PDB number 1WNC). One C-terminal chain is highlighted in gray. The helical region is shown in cartoon form and residues included within the heptad repeats are shown as sidechains.

Considerable genetic and biophysical evidence supports the concept that the ability of the Class I envelope glycoprotein to mediate membrane fusion is determined, in part, by the stability of the six-helix bundle ([@bib11], [@bib16], [@bib35], [@bib43], and references therein). A general model for Class I viral protein-induced membrane fusion posits that the native envelope glycoprotein exists in a metastable state and, upon activation by receptor binding and/or endosomal pH, undergoes a structural reorganization that leads to exposure of the previously constrained fusion subunit and insertion of its hydrophobic "fusion peptide" into the cellular membrane. In this prehairpin intermediate, the fusion subunit is anchored to the viral membrane via its transmembrane domain and to the cellular membrane via the fusion peptide. Collapse of this intermediate leads to a trimer-of-hairpins structure in which the N- and C-terminal heptad-repeat regions assemble as anti-parallel α-helices to form the six-helix bundle, thereby bringing the viral and cellular membranes into apposition. The free energy made available through formation of the highly stable helical bundle is thought to drive fusion of the lipid bilayers. Thus, the kinetics and thermodynamics of six-helix bundle formation are critical determinants of envelope glycoprotein-mediated membrane fusion.

Here, we have utilized scanning mutagenesis to investigate amino acids at the repeating hydrophobic positions throughout the C-terminal heptad-repeat region of the S glycoprotein in order to assess their relative contributions in promoting membrane fusion. We show that serine mutations at only those positions in the short α-helical region of the C-terminal heptad repeats affect the ability of the S glycoprotein to mediate receptor-dependent cell--cell fusion. These findings are consistent with the role of α-helical packing interactions in promoting SARS-CoV S glycoprotein-mediated membrane fusion.

Results
=======

The crystal structure of the six-helix bundle core of the SARS-CoV S glycoprotein contains an extended central trimeric coiled coil of N-terminal heptad-repeat sequences and distinctly shorter C-terminal helices that are limited to two central heptad-repeat units within the longer heptad-repeat sequence (see [Fig. 1](#fig1){ref-type="fig"}). To assess the role of this six-helix structure in promoting membrane fusion, we subjected the C-terminal heptad-repeat region of the S glycoprotein from the Urbani isolate of SARS-CoV ([@bib19]) to scanning mutagenesis. Specifically, we focused on residues at ***a*** and ***d*** positions in the heptad repeats, as these hydrophobic sidechains contribute to interhelical knob-in-hole packing interactions that play a dominant role in stabilizing coiled-coil structures ([@bib8]). These amino acids were individually replaced with serine, a polar residue that would be expected to disturb hydrophobic packing interactions while retaining good α-helix propensity ([@bib6]). Previous studies of the murine coronavirus S glycoprotein suggested that less severe substitutions with individual alanine residues, a small helix-forming amino acid that contributes minimally to hydrophobicity, were insufficient to disrupt six-helix bundle packing ([@bib24]).

Expression of the wild-type and mutant SARS-CoV S glycoproteins in simian COS-7 cells was obtained by transient transfection and was driven by the recombinant vTF7-3 vaccinia virus T7 RNA polymerase ([@bib12]). Metabolically labeled cells were lysed in cold Tris--saline buffer containing 1% Triton X-100, and S glycoproteins were isolated via an S-peptide (Spep) affinity tag ([@bib18]) at the cytoplasmic C-terminus and S-protein agarose (Novagen). The Spep addition is innocuous with regard to S glycoprotein-mediated membrane fusion (not shown), in keeping with reports of other C-terminal tags ([@bib2], [@bib4], [@bib27]). The glycoproteins were then eluted in NuPAGE sample buffer (Invitrogen) containing lithium dodecyl sulfate (LDS) and reducing agent and resolved using NuPAGE 3--8% Tris--acetate gels. As shown in [Fig. 2](#fig2){ref-type="fig"} , each of the wild-type and mutant glycoproteins was expressed to yield the terminally glycosylated glycoprotein of approximately 220 kDa molecular weight, as well as an immature, Endo H-sensitive form of 200 kDa ([@bib2], [@bib38] and K.E.F. and J.H.N, unpublished). The 220-kDa form of the mutant S glycoproteins appeared to migrate somewhat slower than that of the wild type, suggesting a subtle change in terminal glycosylation. Upon deglycosylation with peptide:*N*-glycosidase F (New England BioLabs), all migrated uniformly at the expected 140-kDa molecular weight of the S polypeptide (not shown). As has been reported by others ([@bib2], [@bib34], [@bib38], [@bib44]), we found no evidence of proteolytic maturation of the SARS-CoV S glycoprotein to form discrete S1 and S2 subunits. Expression levels of all the mutant S glycoproteins were generally similar to the wild type, with the exception of A1172S, which was reduced. Higher molecular-weight forms of the glycoproteins were also observed to variable degrees among the wild-type and mutant samples ([Fig. 2](#fig2){ref-type="fig"} and below).Fig. 2Expression of wild-type and mutant S glycoproteins. The metabolically labeled S glycoproteins were affinity isolated and separated using NuPAGE 3--8% Tris--acetate gels (Invitrogen). Samples were heated to 70 °C in sample buffer containing LDS and reducing agent prior to electrophoresis. Fixed and dried gels were visualized using a Fuji-3000G Phosphorimager. Rainbow \[^14^C\]-molecular weight markers (Amersham Pharmacia Biotech) and the 500-kDa HiMark standard (Invitrogen) are indicated. The mature and immature glycoforms of the S glycoprotein are evident, as are very high molecular-weight species. Identical patterns were obtained using the untagged S glycoprotein and immunoprecipitation by MAbs directed to the S1 domain (not shown).

Transport of the S glycoproteins to the cell surface was determined by flow cytometry using the SARS-CoV neutralizing MAb F26G18 ([@bib1]) and was found to be unperturbed in all the mutants, including A1172S ([Fig. 3](#fig3){ref-type="fig"} ). Cell-surface binding of the mutant glycoproteins by other S glycoprotein-directed MAbs (viz., F26G6, F26G8, and F26G19; [@bib1]) was also similar to that of the wild type (not shown). These four MAbs recognize predominantly linear epitopes in the S1 domain ([@bib1]; K.E.F. and J.H.N, unpublished), and thus binding reflects the amount of cell-surface glycoprotein more so than its conformational integrity. Nonetheless, the consistency in cell-surface fluorescence is suggestive of similar transport and presentation. Taken together, these data indicate that none of the serine substitutions markedly affected the biosynthesis or transport to the cell surface of the mutant S glycoproteins.Fig. 3Flow cytometric analysis of cell surface S glycoprotein. COS-7 cells transiently expressing the wild-type and mutants glycoproteins were stained using the SARS-CoV-neutralizing MAb F26G18 and a secondary fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibody. Cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences), and propidium iodide-staining (dead) cells were excluded. Background staining of mock-transfected cells is shown in the first panel by the open histogram; non-expressing cells are also evident in all transfected cell populations. Expressing cells were defined using a gate of ≥30 (\<0.1% of the mock-transfected population). Although the percentages of expressing cells varied (15--30%) with transfection efficiencies, the median fluorescence intensities in all expressing populations were similar (range = 140--180 fluorescence channel).

The ability of the wild-type and mutant S glycoproteins to mediate membrane fusion was assessed by cell--cell fusion using the recombinant vaccinia virus-based β-galactosidase fusion reporter assay ([@bib30]). COS-7 cells expressing the S glycoproteins were co-cultured with COS-7 cells expressing the cell surface receptor of the SARS-CoV, angiotensin converting enzyme 2 (ACE2) ([@bib22]). Cell--cell fusion was detected by the induced expression in syncytia of the β-galactosidase reporter. Cell--cell fusion by the wild-type and mutant S glycoproteins was entirely dependent on expression of the ACE2 receptor (not shown; [@bib22], [@bib44]). In these experiments, the ability of the S glycoproteins to mediate ACE2-dependent cell--cell fusion varied markedly among the mutants ([Fig. 4](#fig4){ref-type="fig"}A). Substitutions at the termini of the heptad-repeat region had no effect on fusogenicity (viz. V1158S, L1179S, and L1182S) whereas more centrally located substitutions produced variable deficiencies ranging from 10% of wild-type activity (for L1168S) to ≈40% of wild-type activity (for I1161S and A1172S).Fig. 4Fusogenicity of wild-type and mutant S glycoproteins. (A) The ability of the S glycoproteins to promote ACE2-dependent cell--cell fusion was detected using the recombinant vaccinia virus-based β-galactosidase-reporter assay ([@bib30], [@bib47]). The number of blue syncytia relative to that in the wild-type S glycoprotein control is shown from two independent experiments, each performed in duplicate; standard deviation is shown as error bars. Transfection efficiencies were comparable in all cases within each experiment. (B) The rendering in [Fig. 1](#fig1){ref-type="fig"} has been annotated to illustrate critical ***a*** and ***d*** heptad-repeat positions relative to the α-helical region.

Interestingly, all the amino acids identified as important for cell--cell fusion in this analysis lie within the short C-terminal α-helix; these ***a*** and ***d*** position sidechains pack directly into the hydrophobic grooves of the N-terminal coiled coil ([Fig. 4](#fig4){ref-type="fig"}B). In the crystal structure, the outlying residues (V1158S, L1179S, and L1182S) exist in an extended non-α-helical conformation of O-X-O repeats ([@bib10], [@bib17], [@bib39], [@bib46]) and are not positioned to interact in a conventional knob-into-hole manner with the N-terminal coiled coil. Instead, both V1158 and L1179 utilize main-chain atoms to interact with asparagine and glutamine sidechains on the N-terminal coiled coil ([@bib10]). These interactions are likely undisturbed in the mutant glycoproteins. The convergence between the crystallographic structure of the six-helix bundle and those sidechains critical for membrane fusion provides strong evidence for the central importance of the α-helical bundle in SARS-CoV S glycoprotein-mediated membrane fusion.

It is likely that serine substitutions that affect S glycoprotein-mediated membrane fusion (I1161S, I1165S, L1168S, A1172S, and L1175S) act, in part, by destabilizing the six-helix bundle. Support for this conjecture may be gleaned from an analysis of the higher molecular-weight forms of the S glycoprotein (\>500 kDa) shown in [Fig. 2](#fig2){ref-type="fig"}. These aggregates are stable at 70 °C to disulfide-bond reduction and LDS denaturation and vary in a consistent manner in the extent of their formation. In appearance and stability, these higher molecular-weight forms are reminiscent of the fusion-active oligomers of the avian leukosis retrovirus envelope glycoprotein that are induced upon receptor binding and acidic pH ([@bib26], [@bib28], [@bib29], [@bib36]). Formation of such oligomers may also be triggered by non-physiological means, such as by treatment with nonionic detergent, heat, urea, or guanidium hydrochloride ([@bib5], [@bib33], [@bib41], [@bib42]). It is possible then that the higher molecular-weight forms observed in the SARS-CoV S glycoprotein represent post-fusion oligomers that provide a fortuitous measure of the relative stability of the wild-type and mutant six-helix bundles. In many of the fusion-deficient S glycoproteins (viz., I1161S, L1168S, A1172S, and L1175S), mutations that affect fusogenicity also affect the extent of formation ([Fig. 2](#fig2){ref-type="fig"}) and the thermal stability (not shown) of the higher molecular-weight forms. If borne out in biophysical studies, this interpretation lends additional support to the concept that the formation and stability of the six-helix bundle is intimately coupled to membrane fusion. The I1165S mutant in which fusogenicity is diminished despite the ample formation of the higher molecular-weight species suggests that other parameters may also be important.

Discussion {#sec1}
==========

Our conclusions confirm and extend pioneering findings in another coronavirus species, the prototype murine hepatitis coronavirus (MHV) ([@bib24]). In that work, ***d*** positions in the C-terminal heptad repeats were replaced by alanine. Although single alanine substitutions were insufficient to affect cell--cell fusion, double mutations were highly detrimental and these clustered specifically to the central heptad repeats, and not to the outlying repeats. There too, oligomer formation (as determined by sucrose gradient analysis) correlated with fusogenicity. Translating these early results to the recently determined structure of the MHV six-helix bundle ([@bib45]), which also reveals a short C-terminal helical region, confirms the notion that the α-helix bundle is an important determinant of S glycoprotein-mediated cell--cell fusion and, by extension, critical for viral entry.

Despite the central role of the six-helix bundle structure in promoting membrane fusion, the family of coronaviruses displays an unusual dimorphism in the length of its N- and C-terminal heptad-repeat regions. Coronaviruses that cluster within one serological and phylogenetic grouping, the Group 1 viruses that include the human respiratory isolate 229E and the feline infectious peritonitis virus (FIPV), contain two additional heptad repeats (14 amino acids) at the center of both N- and C-terminal heptad-repeat regions ([@bib39], [@bib46]). It is likely that these inserts extend and increase the stability of the helical regions in these viruses, but biophysical and structural evidence for this suggestion is currently lacking. Interestingly, the S glycoproteins of established coronaviruses that contain the shorter heptad-repeat regions, specifically the Group 2 coronaviruses that include MHV and the bovine CoV, normally undergo proteolytic maturation during biosynthesis to form discrete receptor-binding (S1) and fusion (S2) subunits ([@bib21]). By contrast, the S glycoproteins of the Group 1 coronaviruses encoding the expanded heptad-repeat regions are not subjected to proteolytic cleavage. Although the newly emerged SARS-CoV encodes the shorter heptad-repeat regions and has been phylogenetically associated with the Group 2 coronavirus ([@bib13], [@bib37]), its S glycoprotein does not undergo proteolytic maturation. It is unknown what, if any, relationship exists in the coronaviruses between proteolytic cleavage, activation of the structural reorganization in the S glycoprotein, and formation of the six-helix bundle. The seemingly mixed provenance of the SARS-CoV may have important implications for coronavirus evolution and pathogenesis.

Materials and methods
=====================

Molecular reagents and monoclonal antibodies
--------------------------------------------

The S glycoprotein gene of the Urbani isolate of SARS-CoV ([@bib19]) was obtained from P. Rota (Centers for Disease Control and Prevention, Atlanta) and adapted for expression in pcDNA3.1^−^(Invitrogen). We further modified this plasmid to introduce an S-peptide (Spep) affinity tag ([@bib18]) at the cytoplasmic C-terminus of the S glycoprotein to facilitate manipulations. Serine mutations at ***a*** and ***d*** positions of the C-terminal S2 domain heptad repeats ([Fig. 1](#fig1){ref-type="fig"}) were introduced by using QuikChange mutagenesis (Stratagene) and confirmed by DNA sequencing. A plasmid expressing the cell surface receptor of the SARS-CoV, angiotensin converting enzyme 2 (ACE2), was kindly provided by M. Farzan (Harvard Medical School, Boston) ([@bib22]). Mouse monoclonal antibodies (MAbs) directed to the S glycoprotein were kindly provided by J. Berry (National Center for Foreign Animal Diseases and University of Manitoba, Winnipeg, Canada) ([@bib1], [@bib14]).

Expression of the S glycoprotein
--------------------------------

The full-length S glycoprotein was transiently expressed in COS-7 cells using the pcDNA3.1^−^ T7 promoter and the recombinant vaccinia virus vTF7-3 encoding T7 polymerase ([@bib12]). vTF7-3 was obtained from T. Fuerst and B. Moss (National Institutes of Health) through the NIH AIDS Research and Reference Reagent Program. COS-7 cells were infected with the recombinant vaccinia virus at a multiplicity of eight in Dulbecco\'s Minimal Essential Medium (DMEM) containing 2% fetal bovine serum (FBS). Cytosine arabinoside (araC) was included at 10 μM to limit vaccinia virus expression ([@bib15]). After 30 min, the cells were washed and transfected with the S glycoprotein-expression plasmid using FuGene-6 reagent (Roche Biochemicals). Metabolic labeling using 50 μCi/ml of \[^35^S\]-ProMix (Amersham Pharmacia Biotech) was initiated 6 h post-transfection in methionine- and cysteine-free DMEM containing 10% dialyzed FBS and 10 μM araC, and was continued for 12--16 h. Cultures were then washed in physiological buffered saline (PBS) and lysed using cold Tris--saline buffer (50 mM Tris--HCl and 150 mM NaCl at pH 7.5) containing 1% Triton X-100 nonionic detergent and protease inhibitors (1 μg/ml each of aprotinin, leupeptin, and pepstatin). A soluble fraction was prepared by centrifugation at 15,000×*g* for 30 min at 4 °C. The expressed S glycoproteins were isolated using the Spep affinity tag and S-protein agarose (Novagen) and resolved using NuPAGE 3--8% Tris--acetate gels (Invitrogen) and the recommended sample buffer containing LDS and reducing agent. Samples were heated to 70 °C prior to electrophoresis. Molecular weight markers included \[^14^C\]-methylated Rainbow proteins (Amersham Pharmacia Biotech) and HiMark standards (Invitrogen). Radiolabeled proteins were imaged using a Fuji FLA-3000G imager and analyzed using ImageGauge software (Fuji).

Flow cytometry
--------------

COS-7 cells transiently expressing the wild-type and mutant glycoproteins were labeled using the SARS-CoV-neutralizing MAb F26G18 ([@bib1]) and a secondary fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody (Jackson ImmunoResearch). Cells were subsequently stained using propidium iodide (1 μg/ml) and then fixed in 2% formaldehyde. Populations were analyzed using a FACSCalibur flow cytometer and CellQuest software (BD Biosciences).

S glycoprotein-mediated cell--cell fusion
-----------------------------------------

The β-galactosidase fusion reporter assay ([@bib30]) was used to assess the ability of the wild-type and mutant S glycoproteins to mediate receptor-dependent cell--cell fusion. The recombinant vaccinia virus vCB21R-lacZ expressing β-galactosidase under the control of the T7 promoter ([@bib30]) was obtained from C. Broder, P. Kennedy, and E. Berger (NIH) through the AIDS Research and Reference Reagent Program. In these studies, COS-7 cells infected with vTF7-3 and expressing the S glycoprotein were co-cultured with COS-7 cells transfected to express the SARS-CoV cellular receptor ACE2 ([@bib22]) and infected with vCB21R-lacZ. β-galactosidase expression is induced upon fusion of the effector and target cells ([@bib30]). To generate the target cell population, COS-7 cells that had been transfected one day previously with the ACE2-expression plasmid ([@bib22]) were incubated with vCB21R-lacZ at a multiplicity of 10 and the infection was allowed to proceed overnight in the presence of 100 μg/ml of the vaccinia virus assembly inhibitor, rifampicin. The following day, S glycoprotein-expressing cells and ACE2-expressing target cells were co-cultured for 10 h in medium containing both araC and rifampicin ([@bib15], [@bib47]). Cultures were then fixed for 5 min at 4 °C in cold PBS containing 2% formaldehyde and 0.2% glutaraldehyde, and β-galactosidase activity was detected using the chromogenic X-gal substrate ([@bib30]). The numbers of blue syncytia were determined microscopically.
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